Genentech, Inc.
NEWS
Xofluza showed a significant preventive effect after a single oral dose. Only about 1.9% of patients who received Xofluza showed signs of the flu, compared to 13.6% of the placebo group.
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus’ technology to target IBD and Celiac.
The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
The FDA rapidly reviewed and approved the medication under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot program.
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson. Start Codon is a strategic initiative that’s targeting translating research into commercial companies.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
JOBS
IN THE PRESS